Mechanical Ventilation and Acute Kidney Injury by Kuiper, J.W.
Chapter 3 
 
 
Renal injury through systemic mediator release - just theory or a causal 
relationship?  
 
J.W. Kuiper 
R. Vaschetto 
F. Della Corte 
F.B. Plötz 
A.B.J. Groeneveld    
 
Published in Critical Care  2011; 15: 228 
Chapter 3
38
Abstract  
 
We review the current literature on the molecular mechanisms involved in the pathogenesis of 
acute kidney injury induced by plasma mediators released by mechanical ventilation. A 
comprehensive literature search in the PubMed database was performed and articles were 
identified that showed increased plasma levels of mediators where the increase was solely 
attributable to mechanical ventilation. A subsequent search revealed articles delineating the 
potential effects of each mediator on the kidney or kidney cells. Limited research has focused 
specifically on the relationship between mechanical ventilation and acute kidney injury. Only a 
limited number of plasma mediators has been implicated in mechanical ventilation-associated 
acute kidney injury. The number of mediators released during mechanical ventilation is far 
greater and includes pro- and anti-inflammatory mediators, but also mediators involved in 
coagulation, fibrinolysis, cell adhesion, apoptosis and cell growth. The potential effects of these 
mediators is pleiotropic and include effects on inflammation, cell recruitment, adhesion and 
infiltration, apoptosis and necrosis, vasoactivity, cell proliferation, coagulation and fibrinolysis, 
transporter regulation, lipid metabolism and cell signaling. Most research has focused on 
inflammatory and chemotactic mediators. There is a great disparity of knowledge of potential 
effects on the kidney between different mediators. From a theoretical point of view, the systemic 
release of several mediators induced by mechanical ventilation may play an important role in the 
pathophysiology of acute kidney injury. However, evidence supporting a causal relationship is 
lacking for the studied mediators.  
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Introduction  
 
Acute kidney injury (AKI) is a common problem in critically ill patients and carries significant 
morbidity and mortality. Based on a recent multinational study, the incidence of AKI is estimated 
to be 5.7%, with a mortality of 60%.1 AKI rarely occurs in isolation but usually develops in the 
context of multiple organ failure. Despite advances in dialysis technology and supportive care, 
mortality resulting from AKI has remained unchanged over the past years and is as high as 80% 
when associated with respiratory insufficiency.1,2 An observational study recently found that 75% 
of all patients with acute respiratory failure required some form of renal replacement therapy. 1 
 
Mechanical ventilation (MV) is an independent risk factor for the development of AKI and can 
contribute to its development by three proposed mechanisms: blood gas disturbances leading 
to hypoxemia or hypercapnia and subsequent neurohumoral-mediated  effects on renal blood 
flow during MV; changes in cardiac output, redistribution of intra-renal blood flow and 
stimulation of hormonal and sympathetic pathways may affect systemic and renal 
hemodynamics, thereby decreasing renal blood flow; and MV-induced biotrauma, defined as a 
pulmonary inflammatory reaction to MV with pulmonary mediator release.1,3 Subsequent spill-
over of these mediators into the systemic circulation may contribute to AKI.4  
 
Although various processes play significant roles in the pathophysiology of AKI, this review 
focuses specifically on the potential role of plasma mediators released as a result of MV in the 
pathogenesis of AKI. First, we review the current clinical and experimental literature describing 
mediators that are systemically released during MV and their effect on the kidney. The causality 
of the relationship between systemically released mediators and AKI will be explored. Second, 
we identify mediators whose release is attributable to MV and discuss the potential effects of 
these mediators on the kidney. This will provide a framework for future research on ventilation-
induced renal injury through systemic mediator release.   
 
 
Methods  
 
We performed an extensive literature search in PubMed using medical subject headings and text 
words, supplemented by scanning the bibliographies of the recovered articles. We combined 
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‘acute renal failure’ and ‘acute kidney injury’ using the term ‘OR’. This search was subsequently 
combined with ‘mechanical ventilation’ using the Boolean operator ‘AND’. Using a similar search 
strategy, using ‘mediator’ and ‘cytokine’ we identified 19 different plasma mediators that 
increased during MV. We included only in vivo studies in which the increase in plasma mediator 
levels was exclusively attributable to MV. We excluded neurohumorally increased mediators, 
mediators increased in renal tissue samples and mediators derived from in vitro experiments 
exposing cell cultures to mechanical stretch. Each mediator was searched in PubMed, also 
including alternative names and abbreviations. We combined these results with the terms 
‘glomerular’, ‘glomerulus’, ‘tubular’, ‘mesangial’, ‘mesangium’, ‘podocyte’, ‘acute renal failure’ and 
‘acute kidney injury’. To delineate the potential effects of these mediators on the kidney, we 
limited the articles to studies that solely studied effects on the kidney or on different kidney cell 
types.  
 
 
Mechanical ventilation, systemic mediator release and the kidney  
 
The importance of MV in morbidity and mortality of patients suffering from acute respiratory 
distress syndrome is stressed by the 2000 landmark study by the ARDS Network. In this multi-
center trial, lung protective ventilation decreased morbidity and mortality rates compared to a 
conventional strategy.5 Although the exact mechanisms remain unknown, the biological 
response of the lungs to the effects of MV was aptly named biotrauma to describe the ongoing 
changes in pulmonary inflammation and the systemic release of inflammatory mediators.6 The 
biotrauma hypothesis is supported by evidence from experimental models ranging from 
mechanically stressed cell systems to isolated lungs, intact animals, and humans.7 Various 
mechanisms are responsible for the ventilation-induced release of mediators. There are four 
principal mechanisms, all of which appear to be clinically relevant: stress failure of the plasma 
membrane (necrosis); stress failure of endothelial and epithelial barriers 
(decompartmentalization); over distension without tissue destruction (mechanotransduction); 
and  effects on vasculature, independent of stretch and rupture.8 The possible effects of 
systemically released and circulating mediators during ventilator-induced lung injury on organs 
distant from the lungs has prompted research to focus on the potential effects of mediators on 
the kidney (Table 1). Thus far only one clinical study has compared a conventional MV strategy 
with a lung-protective strategy in patients with acute respiratory distress syndrome. This single-
center study found increased kidney failure in the conventional strategy group.  
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A correlation was found between plasma IL-6 levels and the number of failing organs in the same 
patients.9 In these patients an association between plasma soluble Fas ligand (sFasL) levels and 
changes in creatinine was also found.10 The authors conclude that mediator release during MV is 
correlated to the development of multi-organ failure and these findings may partially explain the 
decrease in morbidity and mortality in patients ventilated with a lung protective strategy. In 
animal experiments the role of MV on the kidney was further explored, focusing on the role of 
pro-inflammatory mediators,11-14 renal apoptosis,10 vasoactive mediators and renal blood flow,15  
Table 1. Effects of mechanical ventilation on the kidney 
 
Reference Model/injury Ventilation strategy Plasma 
mediators 
Renal endpoints 
Ranieri et al. 
20009 
ARDS patients 11 ml/kg, PEEP 6 vs. 8 
ml/kg, PEEP 15 
IL-6, TNF-α, 
IL-1β, IL-8 
Renal failure according to 
Knaus 
Choi et al. 
200318 
Healthy rats 20 ml/kg vs. 7 ml/kg VEGF Proteinuria, albuminuria, 
eNOS expression, 
microvascular leak 
Gurkan et 
al. 2003200 
Acid aspiration  in 
mice 
17ml/kg, PEEP 3 vs. 6 
ml/kg, PEEP 3 
 Il-6, VEGFR-2 expression 
Imai et al. 
200310 
Acid aspiration in 
rabbits 
15-17 ml/kg, PEEP 0-3 
vs. 5-7 ml/kg, PEEP 9-
12 
MCP-1, IL-8, 
GRO, sFasL 
Creatinine, apoptosis, 
histological changes with 
EM 
Crimi et al. 
200611 
Hemorrhagic shock 
and resuscitation in 
rats 
12 ml/kg, PEEP 0 vs. 6 
ml/kg PEEP 5 
IL-6, MIP-2 Creatinine, apoptosis 
Dhanireddy 
et al. 200612 
Bacterial aspiration 
(S. aureus) in mice 
Spontaneous 
breathing vs. 10 ml/kg 
IL-6, KC, 
MIP-2 
Creatinine 
O’Mahony 
et al. 200613 
LPS i.p. in mice Spontaneous 
breathing vs. 10 ml/kg 
IL-6, KC, 
MIP-2, TNF-
α 
Creatinine 
Kuiper et al. 
200815 
Healthy rats 20 cm H2O, PEEP 2 vs. 
14 cm H2O PEEP 5 
 Decrased renal blood flow, 
increased renal ET-1 
Vaschetto et 
al. 200814 
LPS aspiration in 
rats 
15 ml/kg, PEEP 0 vs. 6 
ml/kg PEEP 5. 
IL-6, TNF-α Kidney apoptosis 
Decreased creatinine 
clearance 
Hegeman et 
al. 2009201 
Healthy mice 20 cm H2O, PEEP 0 for 
1, 2, 4 hrs vs. 
spontaneous 
breathing 
 Increased E-selectin, VCAM-
1, ICAM-1, PECAM-1, IL-1?, 
KC mRNA expression. 
Increased MPO activity 
Kobr et al. 
200926 
Healthy piglets 10 ml/kg vs. 6 ml/kg  
vs. spontaneous 
breathing 
VCAM-1, 
ICAM-1 
Decreased creatinine 
clearance and free water 
clearance 
 
ARDS, acute respiratory distress syndrome; EM, electron microscopy; eNOS, endothelial nitric oxide 
synthase; ET, endothelin; ICAM, intercellular adhesion molecule; i.p., intraperitoneal; LPS, 
lipopolysaccharide; GRO, growth-regulated oncogene; KC, keratinocyte-derived chemokine; MCP, 
monocyte chemoattractant protein; MIP, macrophage infl ammatory protein; MPO, myeloperoxidase; 
PECAM, platelet endothelial cell adhesion molecule; PEEP, positive end-expiratory pressure (in cmH2O); 
sFasL, soluble Fas ligand; VCAM, vascular cell adhesion molecule; VEGF, vascular endothelial growth 
factor; VEGFR2, vascular endothelial growth factor receptor 2. 
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Table 2. Plasma mediator release during mechanical ventilation; patient and animal data 
 
Reference Model/injury Ventilation strategy Systemic mediators 
Calfee et al.19 ICU patients 12 ml/kg vs. 6 ml/kg sICAM-1 
Eisner et al.20 ICU patients 12 ml/kg vs. 6 ml/kg SP-D 
Parsons et al.21 ICU patients 12 ml/kg vs. 6 ml/kg IL-6, IL-8 
Parsons et al.22 ICU patients 12 ml/kg vs. 6 ml/kg sTNFR-1 
Ranieri et al.23 ARDS patients 11 ml/kg, PEEP 6 vs. 8 ml/kg, PEEP 15 TNF-?, IL-1?, IL-6, IL-
8, IL-1RA, sTNFR-
55/75 
Stuber et al.24 ICU patients 12 ml/kg, PEEP 5 vs. 5 ml/kg PEEP 15 IL-6, TNF-?, IL-10, IL-
1RA 
ARDS Network5 ICU patients 12 ml/kg vs. 6 ml/kg IL-6 
Ware et al.25 ICU patients 12 ml/kg vs. 6 ml/kg PAI-1, aPC 
Chen et al.17 Healthy rats Non-ventilated vs. 40 ml/kg Active PAI-1 
Chiumello et al.202 Acid aspiration in rats 16 ml/kg vs. 16 ml/kg, 5 PEEP vs. 9 
ml/kg vs. 9 ml/kg, 5 PEEP vs. same 
with recruitment maneuvers 
TNF-?, MIP-2 
Choi et al.18 Healthy rats 20 ml/kg vs. 7 ml/kg VEGF 
Crimi et al.11 Hemorrhagic shock and 
resuscitation in rats 
12 ml/kg, PEEP 0 vs. 6 ml/kg PEEP 5 IL-6, MIP-2 
Dhanireddy et 
al.12 
S. aureus aspiration in 
mice 
SB vs. 10 ml/kg IL-6, KC, MIP-2 
Guery et al.203 Healthy rats 30 ml/kg vs. 10 ml/kg TNF-? 
Haitsma et al.16 Pneumonia in rats 12 ml/kg vs. 6 ml/kg, PEEP 5, vs. SB TATc, active tPA 
Haitsma et al.204 LPS aspiration and i.p. 
in rats 
45 cm H2O vs. 45 cm H2O, PEEP 10 TNF-? 
Haitsma et al.205 LPS aspiration and i.p. 
in rats 
45 cm H2O vs. 45 cm H2O, PEEP 10 TNF-? 
Haitsma et al.206 Healthy rats 32 cm H2O vs. 32 cm H2O, PEEP 6 vs. 
13 cm H2O PEEP3 
IL-6, MIP-2 
Herrera et al.207 Septic rats 20 ml/kg vs. 6 ml/kg vs. 20 ml/kg, 
PEEP AIP vs. 6 ml/kg, PEEP AIP 
TNF-?, IL-6 
Imai et al.10 Acid aspiration in 
rabbits 
15-17 ml/kg, PEEP 0-3 vs. 5-7 ml/kg, 
PEEP 9-12 
MCP-1, IL-8, GRO, 
sFasL 
Kobr et al.26 Healthy piglets SB vs. 6 ml/kg vs. 10 ml/kg VCAM-1, ICAM-1 
Murphy et al.208 LPS aspiration in 
rabbits 
12 ml/kg vs. 5 ml/kg, PEEP 10-12 TNF-? 
Oliveira-Junior et 
al.209 
Healthy rats 42 ml/kg vs. 7 ml/kg TNF-?, IL-1? 
O’Mahony et al.13 LPS i.p. in mice SB vs. 10 ml/kg IL-6, KC, MIP-2, TNF-α 
Schortgen et al.210 P. aeruginosa aspiration 
in rats 
27 ml/kg vs. 6 ml/kg vs. 6 ml/kg, 
PEEP 8 vs. PLV vs. SB  
TNF-? 
Vaschetto et al.14 LPS aspiration in rats 15 ml/kg, PEEP 0 vs. 6 ml/kg PEEP 5. IL-6, TNF-α 
Vreugdenhil et 
al.211 
Healthy rats 32 cm H2O vs. 32 cm H2O, PEEP 6 vs. 
14 cm H2O, PEEP 6 
MIP-2,  
Wolthuis et al.212 Healthy mice 15 ml/kg vs. 8 ml/kg IL-6, KC 
 
AIP, above infl ection point; aPC, activated protein C; ARDS, acute respiratory distress syndrome; GRO, 
growth-regulated oncogene; ICAM, intercellular adhesion molecule; IL-1RA, interleukin-1 receptor 
antagonist; i.p., intraperitoneal; KC, keratinocyte-derived chemokine; LPS, lipopolysaccharide; MCP, 
monocyte chemoattractant protein; MIP, macrophage infl ammatory protein; PAI, plasminogen 
activator inhibitor; PEEP, positive end-expiratory pressure (in cmH2O); PLV, partial liquid ventilation; SB, 
spontaneous breathing; sFasL, soluble Fas ligand; sICAM, soluble intercellular adhesion molecule; SP-D, 
surfactant protein D; sTNFR, soluble TNF-α receptor; TATc, thrombin-antithrombin complex; tPA, tissue-
type plasminogen activator; VCAM, vascular cell adhesion molecule; VEGF, vascular endothelial growth 
factor 
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coagulation and fibrinolysis,16,17 and other mediators such as vascular endothelial growth factor 
(VEGF) (Table 1).18 Of specific importance is the previously mentioned study by Imai and 
colleagues. In contrast to other animal studies that are observational by nature, this is the only 
study that used specific blocking of mediators, albeit in vitro. Imai and colleagues found 
increased renal apoptosis after injurious ventilation in rabbits. In vitro blocking of sFasL 
prevented induction of apoptosis of cultured kidney cells by plasma from rabbits ventilated with 
an injurious ventilatory strategy.10 Although limited in number, studies linking MV with acute 
respiratory failure have discovered several new potential pathways in addition to pro-
inflammatory pathways through which MV may cause acute respiratory failure. To date, however, 
no study has established a causal relationship between specific mediators and acute respiratory 
failure during MV in vivo through, for instance, intervention studies where the release of 
mediators is prevented or by blocking released mediators.  
 
Table 2 shows the mediators whose increased release was attributable to MV. Several clinical 
studies identified a large number of plasma mediators.5,19-24 These plasma mediators are not only 
pro-inflammatory by nature, but anti-inflammatory mediators have been identified as well.22-24 
Furthermore, identified mediators are also involved in coagulation, fibrinolysis, cell adhesion and 
surfactant homeostasis.5,19-26 Most research has focused on pro- and anti-inflammatory mediators 
as well as chemokines, and only limited studies have outlined a role for mediators primarily 
involved in cell growth and differentiation or apoptosis (Table 2).10,18 A more indepth analysis of 
the various mediators summarized in Table 2 may provide new therapeutic insights.  
 
 
Potential  effects of mediators on the kidney  
 
Pro-inflammatory  
Tumor necrosis factor-α  
In 1986 Tracey and colleagues27 administered TNF-α intravenously to rats and observed, among 
other things, hypotension, metabolic acidosis, hemoconcentration, acute tubular necrosis and 
death. This pleiotropic character of TNF-α is reflected by its multitude of  effects on the kidney.28 
TNF-α has been implicated in renal inflammation, inflammatory cell recruitment, adhesion and 
infiltration, apoptosis and necrosis, vasoconstriction and vasodilatation, alterations in cell 
morphology and proliferation, coagulation and fibrinolysis, downregulation of urea, glucose, 
sodium and chloride transporters and renal lipid metabolism and signaling (Table 3). TNF-α, 
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through activation of NF-κB, induces its own expression by mesangial cells,29-31 podocytes,32-34 
and tubular epithelial cells.35,36  
 
In a TNF-α receptor knock-out mouse model of cisplatin nephrotoxicity and renal tubular 
epithelial cells, TNF-α increased gene expression of a variety of inflammatory mediators, such as 
transforming growth factor-β, RANTES (regulated upon activation, normal T-cell expressed, and 
secreted), IL-1β, TNF-α, T-cell activation-3, IL-6 and IL-8 (see Table 3 for a complete list).37-42 TNF-α 
is also capable of increasing expression of major histocompatibility complex (MHC) I on 
mesangial cells,43 which indicates the stimulation of antigen-presenting properties by mesangial 
cells under inflammatory circumstances. In vitro exposure of mesangial cells and tubular 
epithelial cells to TNF-α increased expression of CC and CXC chemokines (Table 3), which are 
involved in neutrophil, monocyte and T-lymphocyte recruitment.44-46 In both tubular epithelial 
cell monolayer and tubular epithelial and endothelial cell bilayer experiments, TNF-α increased 
leukocyte transmigration.41,42 By increasing the expression of intercellular adhesion molecule 
(ICAM)-1, vascular cell adhesion molecule (VCAM)-1 and L-selectin on mesangial cells and 
glomerular endothelial cells, TNF-α also facilitates leukocyte adhesion and infiltration into the 
kidney.47-49  
 
Both in vitro and in vivo studies have shown that TNF- α induces caspase 8-dependent apoptosis 
of renal tubular cells and renal endothelial cells by binding to either the TNF-receptor-1 or Fas-
receptor.50-53 In glomerular endothelial cells, cytochrome c influx in the cytosol was found after 
TNF-α stimulation, suggesting a role in the mitochondrial pathway as well.54 Ceramide is an 
important signaling molecule in cellular responses, including apoptosis.55 In both mesangial cells 
and glomerular endothelial cells TNF-α stimulated ceramide formation, but only in the latter did 
this lead to increased apoptosis.56,57 TNF-α also suppresses expression of anti-apoptotic proteins, 
both in vitro and in vivo.53,54 Hruby and colleagues58 showed in vitro that TNF-α induced cytolysis 
in mesangial cells, but not in glomerular epithelial cells. This may be partially attributable to the 
TNF-α-induced production of reactive oxygen species by mesangial cells.59  
 
TNF-α stimulates mesangial cells to produce a variety of vasoactive mediators in vitro (Table 3).60-
69 Piepot and colleagues70 showed impaired endothelium-dependent arterial relaxation after 
TNF-α exposure. By disturbing the balance between vasoconstriction and vasodilatation, TNF-α is 
thus potentially capable of reducing glomerular blood flow and glomerular filtration rate.71 
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Additionally, TNF-α induced downregulation of angiotensin (Ang)-II type-1 receptor expression 
in vivo, which may explain the frequently observed vasodilation during sepsis.72 
 
Tubular epithelial cell shedding and tubular obstruction play a role in renal dysfunction. Glynne 
and colleagues73 incubated proximal tubular epithelial cells with TNF-α and observed disruption 
of the actin cytoskeleton and elongation of cells and shedding of viable, apoptotic and necrotic 
cells dependent on nitric oxide (NO). Cell shedding was accompanied by dispersal of β1-integrins 
and E-cadherin. The same authors also found decreased proximal tubule epithelial cell 
proliferation, an effect that was also observed in mesangial cells.73,74  
 
TNF-α-induced histologic kidney damage is frequently characterized by glomerular fibrin 
deposition. By stimulating renal plasminogen activator inhibitor (PAI)-1 gene expression and 
increasing the production of tissue factor by mesangial and endothelial cells, TNF-α can 
contribute to fibrin deposition.75,76 In a series of animal experiments, Schmidt and colleagues77-80 
hypothesized a role for urea, glucose, sodium and chloride transporters in sepsis-associated 
tubular dysfunction. Within hours after lipopolysaccharide injection in mice they showed 
decreased renal blood flow and glomerular filtration and impaired tubular sodium handling 
associated with decreased levels of the aforementioned transporters. In TNF-α-challenged mice 
they found significant downregulation of genes coding for urea, glucose, sodium and chloride 
transporters as well as for chloride channels and Na+/K+-ATPase-α1 compared to wild-type mice.  
 
In proximal tubule cells in vitro, TNF-α caused a downregulation of gene expression of the 
nuclear hormone receptor liver X receptor/retinoid X receptor (LXR) and several of its target 
genes and coactivators.81 During the acute phase TNF-α interferes with lipid metabolism in the 
kidney, with potential subsequent  effects on the anti-infective and anti-inflammatory properties 
of lipids.82  
 
Interleukin-1β  
Cells of the innate immune system recognize microbial products and products released from 
dying and damaged cells, leading to the formation of complex proteins, termed 
inflammasomes.83,84 Activation of caspase 1 by the inflammasome leads to cleavage and 
subsequent activation of IL-1β.85 Glomerular endothelial cells, cortical tubular epithelial cells, 
podocytes and mesangial cells are capable of IL-1β production.86 Despite its central role in the 
response to cell damage and microbes, surprisingly little in vivo research has focused on the role 
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of IL-1β in acute kidney disease. IL-1β has been implicated in inflammation and cell recruitment, 
vasoactivity, coagulation and fibrinolysis, and regulation of chloride, urea, sodium and glucose 
transporters (Table 3).  
 
Through NF-κB signaling IL-1β stimulates human renal proximal tubular epithelial cells to 
produce IL-6.87 In mesangial cells, others showed IL-1β-driven expression of ceramide, IL-6, IL-8 
and leukemia inhibitory factor.40,50,88,89 Like TNF-α, IL-1β is also capable of upregulating MHC class 
I expression in mesangial cells.43  
 
In mesangial and epithelial cell cultures, IL-1β induced upregulation of a multitude of 
chemoattractants, including CC and CXC chemokines.45,90-92 Following chemo attraction, IL-1β 
also stimulates expression of ICAM-1 on mesangial cells, thereby facilitating leukocyte 
adhesion.93 
 
IL-1β is also involved in hemodynamic instability during septic shock. By downregulating Ang-II 
type-I receptors, IL-1β may be partially responsible for the decreased reactivity to 
vasoconstrictors.72 Additionally, in mesangial cells, IL-1β, through inducible nitric oxide synthase 
(iNOS), caused increased production of NO, known for its vasodilatatory  effects, and 
prostaglandin (PG)E2, which has potential vasodilatory properties.39,94,95  
 
Data on the  effects of IL-1β cell proliferation are limited. Tateyama and colleagues39,96 showed 
that IL-1β could function as an autocrine growth factor for rat glomerular epithelial cells in vitro.  
 
IL-1β can affect both coagulation and fibrinolysis in vitro. In mesangial cells, IL-1β upregulated 
tissue factor expression by a protein kinase C-dependent pathway, with an effect on tissue factor 
activity only when cells were rendered apoptotic.97 Also in these cells, IL-1β was capable of 
inducing the fibrinolytic enzyme tissue type plasminogen activator (tPA), but also its inhibitor 
PAI-1.98 The effects of IL-1β on coagulation and fibrinolysis in the kidney in vivo remain unknown.  
 
In the aforementioned series of animal experiments, Schmidt and colleagues77-80 also found that 
IL-1β- challenged mice significantly downregulated genes coding for urea, glucose, sodium and 
chloride trans porters as well as for chloride channels and Na+/K+-ATPase-α1 compared to wild-
type mice. This implicates IL-1β in sepsis-associated tubular dysfunction with decreased 
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glomerular filtration rate, failure of urine concentration, decreased urine osmolality, increased 
fractional sodium excretion and glucosuria.  
 
In human proximal tubule cells in vitro, IL-1β, like TNF-α, caused downregulation of gene 
expression of the nuclear hormone receptor LXR and several of its target genes and also of its 
coactivators.81 The authors suggest a role for IL-1β in lipid metabolism in the kidney during the 
acute phase.  
 
Interleukin-6  
The exact nature of IL-6 remains the subject of debate - it has been extensively described as both 
pro- and anti-inflammatory.99,100 IL-6 levels increase during hypoxia, tissue damage and organ 
failure101-103 and predict mortality in patients with acute renal failure.104 In the kidney, IL-6 is 
involved in inflammation, leukocyte adhesion and infiltration, apoptosis and survival, 
vasoactivity, prevention of oxidative stress, cell proliferation and lipid homeostasis during the 
acute phase (Table 3).  
 
Ischemia/reperfusion (I/R) studies with IL-6 knock-out mice showed decreased levels of renal 
TNF-α and IL-1β compared to wild type;105 this was accompanied by downregulated expression 
of ICAM-1 and P-selectin and decreased neutrophil infiltration.105-107  
 
The role of IL-6 in apoptosis and survival is complex. In cisplatin-induced renal failure, mice 
lacking IL-6 had better survival rates despite decreased renal function. This was associated with 
upregulation of both pro- and anti-apoptotic genes.108 The authors explain these phenomena by 
the fact that the upregulation of proapoptotic genes disappears after 24 hours, while 
antiapoptotic genes remain upregulated for 72 hours.108 Others also found a positive effect on 
survival in IL-6 knock-out mice with improved renal function.105,106  
 
In mice exposed to intravenous IL-6, Schmidt and colleagues72 found decreased expression of 
Ang-II type-I receptors, which are involved in vasoconstriction, potentially explaining 
vasodilatation during shock. In an I/R model and a mercury chloride-induced model of acute 
renal failure, IL-6 knock-out mice and mice treated with anti-IL-6 antibodies had lower levels of 
oxidative stress and NO-dependent oxidative stress. In addition, IL-6 bound to soluble IL-6 
receptor, likely shedded from neutrophils during AKI, increased gene expression of heme 
oxygenase-1 and restriction factor-1, both known to protect against oxidative stress.105,106  
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Table 3. Potential effects on the kidney of mediators released during mechanical ventilation 
 
Mediator Effects on kidney References 
Pro-
Inflammatory 
  
TNF-? - Stimulated expression of TGF-B, RANTES, MIP-2, MCP-2, IL-1β, TNF-a, 
T-cell activation 3, IL-6, phospholipase-A2, LIF. MHC-I upregulation  
- Leukocyte infiltration through  MCSF, MCP-1, GRO-α, β, γ, ENA-78, 
GCP-2, IL-8, MIP-1β, 3α, RANTES, ICAM-1, VCAM-1, L-selectin 
- Death receptor and mitochondrial mediated apoptosis and ceramide 
signaling. Necrosis through ROS. Downregulation of anti-apoptotic 
proteins. 
- Production of vasoactive mediators: PAF, ET-1, PGs, adenosine, 
NO.Downregulation Ang-II-R 
- NO tubular epithelial cell shedding. Decreased proliferation of tubular 
and mesangial cells 
- Increased PAI-1 gene expression, increased TF production with fibrin 
deposition 
- Decreased gene expression for urea, glucose, sodium and chloride 
transporters/channels 
- Decreased gene expression of nuclear hormone receptor LXR, its 
target genes and coactivators 
37-40, 43 
 
44-49 
 
50-54,56-59 
 
 
60-69,72 
 
73,74 
 
75,76 
 
77-80 
 
81 
IL-1? - Stimulated expression of IL-6, IL-8, LIF, ceramide, MHC-I upregulation 
- Increased expression of MCP-1 GMCSF, MSF, ENA-78, RANTES, MIP-1β, 
ICAM-1 
- Downregulation of Ang-II-R. Expression of NO, PGE2 
- Stimulated growth of glomerular epithelial cells 
- Increased TF expression and activity, upregulation of tPA and PAI-1 
- Decreased gene expression for urea, glucose, sodium and chloride 
transporters/channels 
- Decreased gene exression of nuclear hormone receptor LXR, its target 
genes and coactivators 
40,43,87-89 
90-93 
 
39,72,94,95 
96 
97,98 
77-80 
 
81 
IL-6 - TNF-α, IL-1β stimulation. Increased ICAM-1, P-selectin expression with 
neutrophil infiltration 
- Increased survival, upregulation of pro- and anti-apoptotic genes 
- Decreased expression of Ang-II-R 
- Increased oxidative stress, but increased expression HO-1, Ref-1 
- Proliferation of rat mesangial and tubular cells, increased HGF and 
met-c receptor. Conflicting reports. 
- Decreased gene expression for urea, glucose and chloride 
transporters 
- Abrogation of protective effect of hyperlipidemia 
105-107 
 
108 
72 
105,106 
109-111 
 
77-79 
 
115 
Anti-
inflammatory 
  
IL-10 - Decreased synthesis of TNF-α and IL-1β 
- Contradictory effects on ICAM-1 expression and leukocyte infiltration 
- Prevention of apoptosis and necrosis. Decreased cell cycle activity 
- Reduction of VEGF, iNOS and nitrite formation 
- Proliferation of mesangial cells 
118,119 
118,120 
 
118 
118,121 
122-124 
sTNFR - Decreased expression of TNF-α, MCP-1 
- Inhibition of apoptosis, decreased cell proliferation and fibrosis 
71 
128-130 
IL-1RA - Decreased gelatinase B, stromelysin, MCP-1 and IL-8, 
- Decreased ICAM-1 expression and leukocyte infiltration 
132,133 
134-138 
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Table 3. Continued 
 
Mediator Effects on kidney References 
Chemotactic   
IL-8 - Increased COX-1and PGE2expression 
- Alterations glomerular basement membrane sulfate metabolism 
145 
146 
MIP-2 - Increased MCP-1, RANTES, MIP-2 
- Decreased neutrophil influx 
- Decreased fibrin deposition 
151 
152,153 
152 
KC = GRO-α - Increased MCP-1, RANTES, MIP-2, KC 
- Neutrophil infiltration 
- Stimualted proliferation of medullary collecting duct cells 
- Increased COX-1 and PGE2 synthesis 
151 
153 
154 
145 
MCP-1 - Increased IL-6 
- Increased ICAM-1 expression, chemotaxis and haptotaxis, 
monocyte/macrophage infiltration 
- Increased apoptosis 
- Increased fibrosis, TGF-β, collagen deposits 
- Decreased nephrin 
155 
155-165 
 
164 
165-167 
168 
Coagulation/ 
fibrinolysis 
    
Active PAI-1 - Increased leukocyte infiltration 
- Fibrin, collagen deposits, increased fibronectin, TGF-β, decreased 
urokinase and fibrosis  
169 
169-172 
tPA - Conflicting reports on leukocyte infiltration 
- Conflicting reports on fibrosis 
175,178 
175-178 
aPC - Decreased TNF-α, IL-6, IL-8, IL-18 
- Decreased KC, MIP-2, MCP-1, suppression of leukocyte rolling, 
adhesion and infiltration 
- Decreased apoptosis, necrosis 
- Decreased nitrosative stress 
- Decreased adrenomedullin, iNOS, angiotensin (II), ACE. Increased 
renal and peritubular blood flow, decreased permeability 
- Decreased extracellular matrix depositions 
180-182 
180-184 
 
180-185 
185 
180,181,184 
 
180,185 
Miscellaneous   
VEGF - Decreased MCP-1, ICAM-1, leukocyte infiltration 
- Decreased apoptosis and necrosis 
- Stimulated eNOS and NO expression 
- Incraesed permeability 
- Incraesed proliferation of glomerular cells, podocytes, mesangial cells 
fibroblasts and capillairies 
- Conflicting reports of fibrosis and sclerosis 
- Sustained nephrin expression 
188 
189-192 
193,194 
195,196 
192,194,213-220 
 
194,217,219-221 
221 
sFasL - Increased apoptosis 10 
 
ACE, angiotensin converting enzyme; Ang-II-R, angiotensin-II receptor; aPC, activated protein C; COX, 
cyclooxygenase; ENA, epithelial neutrophil activating protein; eNOS, endothelial nitric oxide synthase; 
ET, endothelin; GCP, granulocyte chemotactic peptide; GMCSF, granulocyte macrophage colony-
stimulating factor; GRO, growth related oncogene; HGF, hepatocyte growth factor; HO, heme-
oxygenase; ICAM, intercellular adhesion molecule; IL-1RA, interleukin-1 receptor antagonist; iNOS, 
inducible nitric oxide; KC, keratinocyte-derived chemokine; LIF, leukemia inhibitory factor; LXR, liver X 
receptor/retinoid X receptor; MCP, monocyte chemoattractant protein; MCSF, macrophage colony 
stimulating factor; MHC, major histocompatibility complex; MIP, macrophage infl ammatory protein; 
MSF, migration stimulating factor; NO, nitric oxide; PAF, platelet activating factor; PAI, plasminogen 
activator inhibitor; PG, prostaglandin; RANTES, regulated upon activation, normal T-cell expressed, and 
secreted; Ref, restriction factor; ROS, reactive oxygen species; sFasL, soluble Fas ligand; sTNFR, soluble 
TNF-α receptor; TF, tissue factor; TGF, transforming growth factor; tPA, tissue type plasminogen 
activator; VCAM, vascular cell adhesion molecule; VEGF, vascular endothelial growth factor. 
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Conflicting reports delineate a role for IL-6 in proliferation of various kidney cells, associated with 
tissue repair and regeneration (Table 3) [109-114].109-114  
 
Similar to TNF-α and I L-1β, Schmidt and colleagues77-79 hypothesized a role for urea, glucose and 
chloride transporters in sepsis-associated tubular dysfunction with failure of urine concentration, 
decreased urine osmolality and glucosuria. In IL-6-challenged mice they found significant 
downregulation of genes coding for urea, glucose and chloride transporters as well as for 
chloride channels and Na+/K+-ATPase-α1 expression compared to wild-type mice, though to a 
lesser extent than TNF-α and IL-1β.  
 
Poloxamer 407 induces hyperlipidemia that protects against renal I/R dysfunction. This was 
associated with decreased plasma levels of IL-6, but recombinant IL-6 infusion abrogated these  
effects. These results were confirmed in apolipoprotein-E- and angiopoietin-like 3-deficient mice, 
which suffer from hypercholesterolemia and hypolipidemia, respectively.115  
 
Anti-inflammatory  
Interleukin-10 
 IL-10 exerts its anti-inflammatory effect through inhibition of MHC class II-associated antigen 
presen tation and by decreasing circulating levels of CC and CXC chemokines.116 However, in a 
dose-dependent manner, IL-10 can also promote inflammation through  effects on B cells and 
natural killer cells and by stimulating cytokine production.116 Increased levels of IL-10 predicted 
mortality in patients with acute renal failure and, interestingly, patients with specific IL-10 gene 
polymorphisms required less renal support during sepsis from pneumonia.104,117 The  effects of IL-
10 on the kidney involve  effects on inflammation, inflammatory cell recruitment and infiltration, 
apoptosis, necrosis and cell cycle activity, vasoactivity and cell proliferation (Table 3).  
 
In vivo studies in different models of AKI, intra venous IL-10 administration decreased TNF-α 
production and prevented creatinine increase in mice.118 Mesangial cells in vitro showed less 
production of TNF-α and IL-1β after stimulation with lipopolysaccharide in the presence of IL-
10.119 Deng and colleagues118 reported decreased ICAM-1 expression in mice during kidney injury 
and IL-10 injection; histological analysis also revealed decreased cast formation and leukocyte 
infiltration. Contradictory to these findings was an observation made by Chadban and 
colleagues120 showing increased ICAM-1 expression on rat mesangial cells after stimulation with 
IL-10. In mice, administration of IL-10 prevented both apoptosis and necrosis, mainly in the outer 
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stripe of the kidney, after cisplatin and I/R-induced kidney injury. IL-10 also decreased cell cycle 
activity.118 
 
IL-10 addition to glomerular epithelial cells in vitro reduced VEGF, a potent modulator of capillary 
permeability.121 In vivo, IL-10 decreased iNOS, and in in vitro culture of cortical tubule cells, IL-10 
exposure decreased nitrite formation.118  
 
In vitro experiments showed proliferation-stimulating  effects of IL-10 on mesangial cells through 
platelet derived growth factor receptor α and β, but also up regulation of IL-10 mRNA, 
suggesting a possible autocrine mechanism.122-124 These in vitro results were confirmed in vivo.124  
 
Soluble tumor necrosis factor-α receptor  
Cleavage of the extracellular domain of the TNF-α receptor (TNF-αR) leads to soluble TNF-αR 
(sTNF-αR) capable of binding and thereby inactivating TNF-α. Blood sTNF-αR levels predicted 
acute renal failure in patients with septic shock and acute lung injury.125,126 In rats subjected to 
ischemia reperfusion injury, sTNF-αR prevented loss of renal function, and prevented expression 
of TNF-α and monocyte chemotactic protein (MCP)-1.127 Without changes in hypotension, 
apoptosis, leukocyte infiltration or morphology, sTNF-αR preserved glomerular filtration rate, 
suggesting a role for vasoactive mediators [71]. Apoptosis of mesangial cells co-cultured with 
interferon- γ-stimulated macrophages was inhibited by sTNF-αR in vitro.128 In in vivo studies in 
rats with unilateral ureteral obstruction, administration of sTNF-αR decreased tubular and 
interstitial cell proliferation and apoptosis and prevented renal fibrosis (Table 3).129,130  
 
Interleukin-1 receptor antagonist  
IL-1 receptor antagonist (IL-1RA) is a physiological inhibitor of IL-1β activity through competitive 
binding to the IL-1β receptor. Recombinant IL-1RA administration during sepsis showed a 
mortality benefi t of almost 5%.131 In mesangial cells addition of IL-1RA decreased gelatinase B, 
stromelysin, MCP-1 and IL-8 RNA and protein levels after stimulation with IL-1α and IL-1β .132,133 In 
in vivo models of anti-glomerular basement membrane antibody glomerulonephritis and renal 
I/R treatment with IL-1RA resulted in improved kidney func tion, decreased expression of ICAM-1 
and reduced renal histological damage, including decreased infiltration of lymphocytes, 
neutrophils and macrophages and less apoptosis (Table 3).134-138 
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Chemotactic  
Interleukin-8  
The chemokine IL-8 is produced mainly by macrophages, but also by renal tubular epithelial 
cells, mesangial cells and podocytes.139-142 IL-8 levels predict the development of AKI, duration of 
MV and mortality in patients with AKI.104,143,144 Exposure of mesangial cells to IL-8 in vitro leads to 
selective expression of cyclooxygenase (COX)1, but not COX2, and subsequent synthesis of 
PGE2.145 In vivo infusion of IL-8 in rats causes increased albuminuria, mediated through alterations 
of sulfate metabolism by the glomerular basement membrane (Table 3).146 
 
Macrophage inflammatory protein-2  
Macrophage inflammatory protein (MIP)-2, a member of the superfamily of chemokines, is a 
potent chemotactic factor for neutrophils and stimulates the production of other inflammatory 
mediators such as IL-1β and TNF-α.147 In kidneys, mesangial cells and glomerular epithelial cells 
stimulated by NO or IL-1β are capable of synthesizing MIP-2.148-150 Exposure of mesangial cells to 
MIP-2 in vitro stimulates the release of MCP-1, RANTES and also MIP-2.151 Specifi c blocking of 
MIP-2 in in vivo models of shiga toxin-induced renal inflammation and anti-glomerular basement 
membrane antibody glomerulonephritis prevented renal neutrophil influx and fibrin deposition 
and decreased proteinuria (Table 3).152,153  
 
Keratinocyte chemoattractant  
Keratinocyte chemoattractant (KC), also known as growth related oncogene or CXCL1, in 
mesangial cells increased production of pro-inflammatory mediators such as MCP-1, RANTES, 
MIP-2 and KC.151 KC exhibited neutrophil-attracting properties as shown in a mouse model of 
shiga toxin-induced renal injury.153 In vitro KC stimulated proliferation of inner medullary 
collecting duct cells.154 KC also stimulates mesangial cells to produce COX1 and enhances PGE2 
synthesis (Table 3).145  
 
Monocyte chemotactic protein-1  
MCP-1, or chemokine ligand 2, stimulates IL-6 synthesis in vitro through NF-κB and activator 
protein-1 activation.155 In vitro and in several animal models of chronic kidney injury, MCP-1 has 
been shown to increase ICAM-1 expression leading to increased chemotaxis, haptotaxis, 
directional cell motility up a gradient of cellular adhesion sites, and leukocyte infiltration; 
macrophages and monocytes were mainly involved.155-165 In rats transfected with a MCP-1 
antagonist and protein overload proteinuria, decreased numbers of apoptotic cells were 
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observed compared to wild type.164 In models of crescentic nephritis and glomerulonephritis, 
blocking MCP-1 was shown to decrease collagen type I and IV deposition and decrease 
transforming growth factor-β level.165,166 Additionally, MCP-1 increased fibronectin production in 
mesangial cells, whereas fibronectin levels decreased in diabetic MCP-1 knockout mice.167 In vitro 
studies of podocytes showed decreased levels of nephrin, which is necessary for the proper 
functioning of the renal filtration barrier, after exposure to MCP-1 (Table 3).168 
 
 Coagulation and fibrinolysis  
Plasminogen activator inhibitor-1  
In patients with acute lung injury, PAI-1 is a prognostic factor for the development of acute renal 
failure.126 In PAI-1 knock-out models or models overexpressing PAI-1 with anti-glomerular 
basement membrane glomerulonephritis, PAI-1 increases leukocyte infiltration, crescent 
formation, fibrin deposits, fibronectin synthesis and collagen accumulation.169-171 Similar results 
were found in rodents with unilateral ureteral obstruction with increased transforming growth 
factor-β1 levels and decreased levels of urokinase.172 Functionally, PAI-1 knock-out mice showed 
decreased albuminuria in a diabetes model (Table 3).173  
 
Tissue type plasminogen activator  
Similar to PAI-1, tPA is mainly involved in fibrosis through matrix metalloproteinase (MMP)-9 
stimulation, myofibroblast activation and prevention of apoptosis of myofibroblasts and 
fibroblasts.174 In tPA knock-out studies in I/R or unilateral ureteral obstruction models, tPA was 
shown to increase neutrophil influx, but other  effects mainly concerned tissue remodeling, 
although conflicting reports exist (Table 3).175-178 
 
Activated protein C  
In patients with severe sepsis, baseline activated protein C (aPC) levels were inversely associated 
with worsening renal function and/or subsequent dialysis and treatment, whereas treatment 
with aPC was associated with improved renal function.179 The anti-inflammatory  effects of aPC 
are shown in the downregulation of the expression of TNF-α, IL-6, IL-8 and IL-18.180-182 By 
decreasing KC and MIP-2 protein and MCP-1 mRNA, aPC potentially prevents inflammatory cell 
recruitment.181-183 Additionally, aPC suppresses leukocyte rolling and adhesion.184 Histologically 
this leads to decreased leukocyte influx and also decreased renal myelo peroxidase levels.180,181 In 
the same histological specimens, aPC prevented renal necrosis and apoptosis of glomerular and 
endothelial cells and podocytes.180-185 In a model of diabetes, Isermann and colleagues185 found 
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aPC to have an antioxidant effect, decreasing nitrosative stress by decreasing kidney 
nitrotyrosine levels. Positive hemodynamic effects have been observed in various models, 
whereby aPC increased renal blood flow and peritubular flow, potentially by the observed 
decrease in adrenomedullin, iNOS, angiotensinogen mRNA, Ang converting enzyme and Ang-
II.184 Vascular permeability is also decreased by aPC.180,181 The anticoagulant properties of aPC are 
highlighted by a decrease in circulating fibrin degradation products and decreased extracellular 
matrix depositions.180,185 Combined, these  effects of aPC preserve renal function as measured by 
creatinine, blood urea nitrogen levels and proteinuria (Table 3).181-184  
 
Miscellaneous  
Vascular endothelial growth factor  
In a rodent model of ventilator-induced lung injury, Choi and colleagues18 indicated a role for 
VEGF in endothelial NOS-mediated vasopermeability in lungs and kidneys. VEGF is a potent 
endothelial cell mitogen, promotes endothelial cell differentiation and survival, stimulates 
angiogenesis and enhances vascular permeability. While deleterious in some forms of renal 
disease, VEGF may contribute to recovery in others.186,187 
 
In rodent models of glomeruolonephritis, intravenous VEGF decreased MCP-1 and ICAM-1 levels 
with a subsequent decrease in infiltrating leukocytes.188 VEGF prevented glomerular and 
tubulointerstitial cell apoptosis and necrosis in models of hemolytic uremic syndrome and 
mesangio-proliferative nephritis, which was confirmed in vitro.189-192 In vivo VEGF stimulated 
endothelial nitric oxide synthase expression in rats in a remnant kidney model, and in glomerular 
endothelial cells this increased NO expression.193,194 One of the characteristics of VEGF is 
enhancement of vascular permeability; this was confirmed in vitro.195,196 The proliferative  effects 
of VEGF have been well described, both in vivo and in vitro, but these properties are likely of 
limited interest for the development of AKI (Table 3).  
 
Soluble Fas ligand  
sFasL is up to 1,000-fold less active than membrane-ebound FasL in inducing apoptosis and has 
even been suggested to have antagonistic properties.197,198 However, Imai and colleagues10 
showed apoptotic activity of serum of mechanically ventilated rabbits on renal tubular cells in 
vitro, which could be blocked by an anti-sFasL Fas:Ig fusion protein (Table 3).  
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Mediators - theory or causal relationship?  
 
Central in the biotrauma hypothesis is the increase in intra-pulmonary mediator levels and the 
spill-over of these mediators from the lung into the systemic circulation. Several mediators are 
systemically increased during MV (Tables 1 and 2), although the exact cellular origins of the 
systemically measured mediators remains unknown.7 Most of the mediators increased during MV 
have potential and well described  effects on the kidney.  
 
Most studies have focused on pro-inflammatory and chemotactic mediators, especially TNF-α, IL-
6 and MIP-2. The  effects of these pro-inflammatory mediators on the kidney have been studied 
to varying degrees. In vivo evidence indicates that TNF-α can cause and contributes to AKI, in 
contrast to IL-1β and MIP-2, for which sufficient in vivo data are lacking. IL-6 has been shown to 
be involved in AKI, but conflicting reports exist and no definite conclusion can be drawn. Much is 
known about the  effects of anti-inflammatory and chemotactic mediators on the kidney. Strong 
evidence indicates a protective role for anti-inflammatory mediators, especially IL-10, in the 
development of AKI, but insufficient evidence exists to indicate a direct role in AKI for 
chemotactic mediators. Little is known about the potential  effects on the kidney of some 
frequently studied mediators released during MV, such as soluble ICAM, soluble VCAM and sFasL. 
The potential of these mediators will remain unknown in the absence of studies on their possible  
effects on the kidney. Other mediators, for example, aPC and VEGF, have several well known  
effects on the kidney but have received little attention in studies on mediator release during MV. 
Studies of aPC and VEGF during MV have great potential to further delineate the  effects of these 
mediators on the kidney. 
 
 IL-10, IL-8 and aPAI-1 all have predictive value for the development of AKI or AKI-associated 
mortality. Despite this, few studies have focused on the role of MV and, even though their 
increase may be an epiphenomenon, little is known about their potential role in the 
pathophysiology of AKI. Interestingly, we did not identify studies using specific blocking of 
mediators in vivo or specific knock-out models that could establish a causal relationship between 
MV-induced mediator release and AKI. However, we describe a multitude of potential  effects on 
the kidney of several mediators that can be blocked rather specifically now in both animal 
models and humans. For example, anakinra, a synthetic IL-1RA, and infliximab, a monoclonal 
antibody against TNF-α, have found their way into clinical practice.  
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Before targeting mediators to prevent AKI in patients, care must be taken to learn from past 
experiences. Attempting to alter the course of sepsis, numerous studies have targeted a variety 
of mediators in critically ill patients, mainly suffering from sepsis. The rather disappointing results 
of these studies have led to insights into the possible mechanisms of failure in these studies. 
Several issues should be taken into account. The agent’s biological activity, shown in vitro or in 
simple animal models, may not be replicable in humans. Dosage, timing and duration of the 
novel therapy are usually unknown. In most trials in critical care medicine the target population 
is heterogeneous, also including genetic polymorphisms. The complexity of mediator 
interdependency may also require the targeting of multiple mediators simultaneously or 
combined targeting of pro- and anti-inflammatory mediators.  
 
 
Conclusion  
 
From a theoretical point of view, the systemic release of several mediators induced by MV may 
play an important role in the pathophysiology of AKI. However, evidence supporting this 
hypothesis or showing causal relationships is lacking for the studied mediators. Future studies 
should therefore not only focus on the release of mediators during MV and a possible 
relationship with AKI, but should also study in-depth the pathophysiology by which these 
mediators may contribute to AKI.  
 
Abbreviations  
AKI, acute kidney injury; Ang, angiotensin; aPC, activated protein C; COX, cyclooxygenase; ICAM, 
intercellular adhesion molecule; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; iNOS, 
inducible nitric oxide synthase; I/R, ischemia/reperfusion; KC, keratinocyte chemoattractant; LXR, 
liver X-receptor/ retinoid X-receptor; MCP, monocyte chemoattractant protein; MHC, major 
histocompatibility complex; MIP, macrophage inflammatory protein; MV, mechanical ventilation; 
NF, nuclear factor; NO, nitric oxide; PAI, plasminogen activator inhibitor; PG, prostaglandin; sFasL, 
soluble Fas ligand; sTNF-αR, soluble TNF-α receptor; TNF, tumor necrosis factor; TNF-αR, TNF-α 
receptor; tPA, tissue type plasminogen activator; VCAM, vascular cellular adhesion molecule; 
VEGF, vascular endothelial growth factor.  
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